Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 4/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 3/20 | 0.43 |
| ▸ | CTSB | P07858 | 4/20 | 0.42 |
| ▸ | CTSK | P43235 | 4/20 | 0.42 |
| ▸ | CASP6 | P55212 | 2/20 | 0.42 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13202009 | 1.00 | CASP1 (0.47) | CASP1ELANECASP3CTSBCTSK | |
| SCHEMBL13197161 | 0.90 | CASP1 (0.59) | CASP1ELANECASP3CASP6CASP8 | |
| SCHEMBL12946446 | 0.90 | CASP1 (0.59) | CASP1ELANECASP3CASP6CASP8 | |
| SCHEMBL949009 | 0.90 | CASP1 (0.59) | CASP1ELANECASP3CASP6CASP8 | |
| SCHEMBL8402109 | 0.90 | CASP1 (0.59) | CASP1ELANECASP3CASP6CASP8 | |
| SCHEMBL8721803 | 0.80 | CASP1 (0.43) | CASP1ELANECASP3CTSBCTSK | |
| SCHEMBL8649223 | 0.79 | ELANE (0.49) | CASP1ELANECASP3CTSBCTSK | |
| SCHEMBL8247253 | 0.78 | CASP3 (0.67) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL7745119 | 0.78 | CASP3 (0.67) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL30472164 | 0.76 | CASP3 (0.47) | CASP1ELANECASP3CTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772366-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-10 | — | — | US | disclosed |
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1R1 | CASP1 5/4885ELANE 140/4885CASP3 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.